Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
BioMarin said it will present data on VOXZOGO for children with achondroplasia and hypochondroplasia at the ASBMR 2026 Annual Meeting. The release also repeats safety information and notes plans tied to regulatory submissions and a PDUFA target date.
BioMarin said it will present data from 13 studies at the American Society for Bone and Mineral Research annual meeting, including results on VOXZOGO, BMN 333 and BMN 401. The company also noted a recent supplemental NDA submission to the FDA for VOXZOGO in hypochondroplasia.